Colony‐Stimulating Factor Use and Impact on Febrile Neutropenia Among Patients with Newly Diagnosed Breast, Colorectal, or Non–Small Cell Lung Cancer Who Were Receiving Chemotherapy

Sullivan, Sean D.; Blough, David K.; Clarke, Lauren; McDermott, Cara L.; Malin, Jennifer L.; Ramsey, Scott D.

doi:10.1002/phar.1008

Cited by 13 publications

(11 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this regard, the benefit of primary prophylaxis with G-CSF in reducing the incidence of FN was not observed in children with acute myeloid leukemia, adults and elderly adults with solid tumors and lymphomas. [41][42][43][44] Interestingly, primary prophylaxis with G-CSF was not effective in preventing the incidence of neutropenia in women with ovarian cancer treated with carboplatin and paclitaxel. 45 Moreover, our data suggest that G-CSF primary prophylaxis is a risk factor for FN.…”

Section: Discussionmentioning

confidence: 97%

Risk Factors for Febrile Neutropenia in Children With Solid Tumors Treated With Cisplatin-based Chemotherapy

Castelán-Martínez

Rodríguez-Islas

Vargas-Neri

et al. 2016

Journal of Pediatric Hematology/Oncology

View full text Add to dashboard Cite

Febrile neutropenia (FN) is a common and potentially fatal adverse drug reaction of cisplatin-based chemotherapy (CDDPBC) in pediatric patients. Hence, the aim of this study was to determine the incidence and independent risk factors for FN in pediatric patients with solid tumors treated with CDPPBC. Cohort integration was performed in the first cycle of chemotherapy with CDDPBC and patients were followed up to 6 months after the last cycle. FN was defined according to the Common Terminology Criteria for Adverse Events. Relative risks were calculated with confidence intervals at 95% (95% CI) to determine FN risk factors. Multiple logistic regression was performed to identify independent risk factors. One hundred and thirty-nine pediatric patients (median age 7.4 y, range 0.08 to 17 y) were included in the study. FN incidence was 62.5%. Independent risk factors for FN were chemotherapy regimens including anthracyclines (odds ratio [OR]=19.44 [95% CI, 5.40-70.02), hypomagnesaemia (OR=8.20 [95% CI, 1.81-37.14]), and radiotherapy (OR=6.67 [95% CI, 1.24-35.94]). It is therefore concluded that anthracyclines-containing regimens, hypomagnesaemia, and radiotherapy are independent risk factors for FN in patients receiving CDDPBC.

show abstract

Section: Discussionmentioning

confidence: 97%

Risk Factors for Febrile Neutropenia in Children With Solid Tumors Treated With Cisplatin-based Chemotherapy

Castelán-Martínez

Rodríguez-Islas

Vargas-Neri

et al. 2016

Journal of Pediatric Hematology/Oncology

View full text Add to dashboard Cite

show abstract

“…Febrile neutropenia (FN) is defined as the appearance of fever (temperature > 38 °C) or clinical signs of sepsis, in a patient with a neutrophil count of < 500/mm 3 or < 1000/mm 3 pre-nadir [ 1 , 2 ]. It is a common iatrogenic complication, varying in incidence (2–50%), depending on patient-related risk factors, neoplasm, type of chemotherapy, and genetic susceptibility [ 3 – 5 ]. While most patients experience mild episodes, the rate of serious complications (25–30%) and mortality (9–12%) remains elevated in high-risk groups [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

SEOM clinical practice guideline: management and prevention of febrile neutropenia in adults with solid tumors (2018)

et al. 2018

View full text Add to dashboard Cite

Febrile neutropenia (FN) is a common dose-limiting toxicity of chemotherapy, with a profound impact on the evolution of patients with cancer, due to the potential development of serious complications, mortality, delays, and decrease in treatment intensity. This article seeks to present an updated clinical guideline, with recommendations regarding the diagnosis, prevention, and treatment of febrile neutropenia in adults with solid tumors. The aspects covered include how to properly approach the risk of microbial resistances, epidemiological aspects, considerations about the initial empirical approach adapted to the risk, special situations, and prevention of complications. A decision-making algorithm is included for use in the emergency department based on a new, validated tool, the Clinical Index of Stable Febrile Neutropenia, which can be used in patients with solid tumors who appear stable in the initial phase of neutropenic infections, and can help detect those at high risk for complications in whom early discharge must be avoided.

show abstract

“…Numerous studies have documented that chemotherapy is effective in prolonging survival for patents with colorectal cancer, from fluorouracil with calcium leucovorin to more effective combination of oxaliplatin and fluorouracil [7][8][9][10][11][12]. However, chemotherapy as a systematic treatment also leads to a certain degree of side effects by suppressing the production of neutrophils and by cytotoxic effects on the cells, of which anemia and neutropenia are the most common side effects [13][14][15][16][17][18][19][20][21][22]. For this reason, colony-stimulating factors (CSFs) such as filgrastim, pegfilgrastim, or sargramostim are often used to primarily prevent neutropenia from occurring and are also sometime used to treat this condition in those atrisk population [19,20].…”

Section: Introductionmentioning

confidence: 98%

Increasing utilization and predictors of hematopoietic growth factors in patients diagnosed with colorectal cancer: findings from a large national population-based cohort in the USA, 1992–2009

Zhang

Fu²,

Du³

2014

Med Oncol

View full text Add to dashboard Cite

None of previous studies has provided the detailed pattern, variation, and temporal trend in the use of growth factors for patients with colorectal cancer. The aim of the study was to examine the temporal trend and predictors of receiving hematopoietic growth factors in a large nationwide and population-based cohort of patients with colorectal cancer in the USA from 1992 to 2009. We studied 50,768 patients diagnosed with colorectal cancer at age 65-89 years in 1992-2009 in the Surveillance, Epidemiology and End Results areas who received chemotherapy as part of initial therapy within 12 months of diagnosis according to Medicare data. Growth factors were identified for colony-stimulating factors (CSFs) and for erythropoiesis-stimulating agents (ESAs). Overall, 16.3% received CSFs and 26.5% received ESAs with an increase from 0.8 and 1.5% in 1992 to 29.4 and 14.1% in 2009, respectively. Compared with patients diagnosed in 1992-1994, those diagnosed in 1995-1997 were >2 times more likely to receive CSFs and ESAs, whereas patients diagnosed recently in 2007-2009 were >22 times and 4 times to receive CSFs and ESAs, respectively. Gender, marital status, comorbidity scores, geographic area, year of diagnosis, tumor stage, number of lymph nodes, and risk profile for febrile neutropenia were statistically significant predictors of using CSFs and ESAs. There were substantial temporal and geographic variations in the use of hematopoietic growth factors in patients with colorectal cancer following chemotherapy. More studies would be needed to explore the effectiveness of hematopoietic growth factors in preventing and treating neutropenia, anemia, and infection.

show abstract

Colony‐Stimulating Factor Use and Impact on Febrile Neutropenia Among Patients with Newly Diagnosed Breast, Colorectal, or Non–Small Cell Lung Cancer Who Were Receiving Chemotherapy

Cited by 13 publications

References 51 publications

Risk Factors for Febrile Neutropenia in Children With Solid Tumors Treated With Cisplatin-based Chemotherapy

Risk Factors for Febrile Neutropenia in Children With Solid Tumors Treated With Cisplatin-based Chemotherapy

SEOM clinical practice guideline: management and prevention of febrile neutropenia in adults with solid tumors (2018)

Increasing utilization and predictors of hematopoietic growth factors in patients diagnosed with colorectal cancer: findings from a large national population-based cohort in the USA, 1992–2009

Contact Info

Product

Resources

About